Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Regeneron Pharmaceuticals REGN Get Free Report has outperformed the market over the past 15 years by 12.37% on an annualized ...

NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

The stock's rise snapped a four-day losing streak.

Kingsview Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 16.5% in the fourth quarter, according to the company in its most recent ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

Craig-Hallum analyst William Bonello maintained a Buy rating on Repligen (RGEN – Research Report) today. The company’s shares closed yesterday ...

Generac (GNRC) posts strong Q4 earnings, beating estimates as demand for backup generators surges amid U.S. power outages.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Tuesday closed up +0.03%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.28%, and the Nasdaq 100 Index ($IUXX) ...

This was the stock's third consecutive day of losses.

With many biotechs and pharmas needing to fill impending revenue holes coming later in the decade, M&A is posed to pick up, but not until government and regulatory uncertainty settles down. Dealmaking ...